Back to search results

Observational Study of Ritlecitinib for Alopecia Areata

This observational study is looking at how ritlecitinib works in people with alopecia areata (AA), a condition where your immune system attacks your hair follicles, causing hair loss. The study aims to understand how well ritlecitinib helps improve hair growth in people aged 12 and older who have been diagnosed with AA by a dermatologist and are already taking ritlecitinib as part of their regular care. Researchers will measure changes in hair loss using a tool called the Severity of Alopecia Tool (SALT) score after 24 weeks of treatment. This study is currently enrolling about 450 participants.

Study design
This is an observational study involving about 450 participants. It is not specified if it is a specific phase of a clinical trial.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome is measured at 24 weeks from the start of treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06531109

Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib

Recruiting
Not specifiedAges 12+Observational
Pfizer
~450 participants
Updated 2026-07-23 on ClinicalTrials.gov
What's tested:Ritlecitinib

At a glance

Recruiting sites
65 of 81 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage change from baseline in Severity of Alopecia Tool (SALT) score at week 24
Measured over 24 weeks from initiation of the treatment

Conditions

Alopecia Areata

Explore related trials

Alopecia

Where it's being run

81 sites across 33 states
France11
China10
California6
Florida5
Tokyo5
United Kingdom5
Italy4
Alabama2

Study leadership

  • Pfizer CT.gov Call Center · STUDY_DIRECTOR · Pfizer

Who to contact

Pfizer CT.gov Call Center
[email protected]
1-800-718-1021
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Percentage change from baseline in Severity of Alopecia Tool (SALT) score at week 2424 weeks from initiation of the treatment

    SALT score is used to calculate the severity of alopecia areata. Physician calculate it by summing the percentage of hair loss in different regions of scalp.